NCT02649270View on ClinicalTrials.gov

Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

October 31, 2017

Conditions

Psoriasis

Interventions

BIOLOGICAL

T1h

Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.

Trial Locations (1)

100020

Beijing Chao-Yang Hospital, Beijing